Taken together, these results indicate that nuclear p16INK4a expression is a strong predictive factor for LRC after adjustment for other known clinical parameters, suggesting a crucial role for nuclear p16INK4a expression in radiation treatment response and local control of HNSCC patients. The gene discussed is CDKN2A; the disease is head and neck squamous cell carcinoma.